Also trades as: INDV.L (LSE) · $vol 5M
INDV NASDAQ
Indivior Pharmaceuticals Inc
1W: -1.0%
1M: +12.2%
3M: +10.5%
YTD: +4.8%
1Y: +227.4%
3Y: +98.0%
5Y: +263.7%
$37.53
+0.07 (+0.19%)
After Hours: $39.27 (+1.73, +4.62%)
Weekly Expected Move ±5.8%
$33
$35
$37
$39
$41
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.66
Bullish
15 bullish
3 neutral
1 bearish
Articles (7d)
19
Daily Sentiment (7 Days)
Articles (100)
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect?
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Can Encompass Health's Expansion Strategy Make It a Hold for Now?
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
Why Investors Should Stay Neutral on Community Health Stock Now
Acadia Healthcare Stock Soars 82% YTD: Time to Hold or Fold?
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
Indivior Pharmaceuticals Inc. (INDV) Is a Great Choice for 'Trend' Investors, Here's Why
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally
BDTX Shares Gain 11% in a Week: Here's What You Should Know
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
Zacks.com featured highlights include The Vita Coco Company, Indivior Pharmaceuticals and Marathon Petroleum
3 Best Momentum Stocks to Buy Now for Big Upside in May 2026
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?
Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should Know
Best Momentum Stock to Buy for May 5th
Indivior launches $175M accelerated share buyback
Indivior (INDV) Q1 2026 Earnings Transcript
Here's Why Momentum in Indivior Pharmaceuticals Inc. (INDV) Should Keep going
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates
Earnings Scheduled For April 30, 2026
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
Theravance Stock Declines Around 17% in Three Months: Here's Why
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99%
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso Study
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean
3 Stocks With Strong Efficiency Metrics to Strengthen Your Portfolio
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV)
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
Mid-Cap healthcare stocks ranked by quant ratings after earnings season